| I. Background | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 
				 Tumor mutational burden (TMB) shows great promise as a biomarker for immuno-oncology (I-O) therapy response, but progress is hindered by the lack of a standardized TMB measurement by targeted NGS panels, and an absence of TMB reference materials. 
 
 
 計(jì)算數(shù)據(jù)下載: 
 
  | 
		|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||